<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="116316">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01588951</url>
  </required_header>
  <id_info>
    <org_study_id>J1227</org_study_id>
    <secondary_id>NA_00071844</secondary_id>
    <nct_id>NCT01588951</nct_id>
  </id_info>
  <brief_title>Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior</brief_title>
  <official_title>Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the trial is to compare the two-year relapse-free survival (RFS) of
      patients with acute myeloid leukemia (AML), presumed to be at high risk for relapse due to
      the presence of leukemia stem cells (LSCs) in their bone marrow at first complete remission
      (CR1), who receive either standard cytarabine-based chemotherapy or allogeneic stem cell
      transplantation (SCT).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse free survival</measure>
    <time_frame>2 year</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Without LSC, standard cytarabine consolidation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LSC present, randomized to cytarabine consolidation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LSC present, randomized to allogeneic transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine consolidation</intervention_name>
    <description>Cytarabine-based consolidation per institutional standards.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>HiDAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allogeneic transplant</intervention_name>
    <description>Allogeneic stem cell transplant per institutional standards.</description>
    <arm_group_label>Arm 3</arm_group_label>
    <other_name>Bone marrow transplant</other_name>
    <other_name>Stem cell transplant</other_name>
    <other_name>Hematopoietic stem cell transplant</other_name>
    <other_name>BMT</other_name>
    <other_name>HSCT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age greater than or equal to 18 years

          2. Able to give informed consent

          3. New diagnosis of AML, other than APL or poor-risk AML, as defined in section 3.2

        Exclusion criteria:

          1. Has already had a bone marrow biopsy and aspirate to assess remission status after
             induction therapy

          2. Any debilitating medical or psychiatric illness that would preclude ability to give
             informed consent or receive optimal treatment and follow-up

          3. Pregnancy: Women of childbearing potential who are Î²- HCG+
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret Showel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>JHU</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Margaret Showel, MD</last_name>
    <phone>(410) 614-7059</phone>
    <email>mshowel1@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Noah Tucker</last_name>
    <phone>410-614-7833</phone>
    <email>ntucker5@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 24, 2016</lastchanged_date>
  <firstreceived_date>April 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
